Added to YB: 2026-05-29
Pitch date: 2026-05-26
ABVX.PA [neutral]
ABIVAX Société Anonyme
+2.99%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 9.0B
Pitch Price
EUR 110.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
-33.61
P/E
-24.84
EV/Sales
1.7K
Sector
Biotechnology
Category
growth
Abivax (ABVX France): New long‑term data strengthen confidence ahead of phase 3 readout
ABVX.PA (update): Q1 3-yr phase 2a/2b data: 68% of 130 pts in clinical remission at 144 wks after dose cut from 50mg to 25mg; 80% completed follow-up, no new safety issues. Phase 3 ABTECT UC maintenance results due end Q2 2026, regulatory filing Q4 if positive. Phase 2b Crohn's results end 2026 (larger commercial opp). €491.6M cash through Q4 2027. R&D up €10.2M YoY to €49.5M on new indications, manufacturing prep.
Read full article (2 min)